These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35550406)

  • 1. Adjuvant Apatinib in Nasopharyngeal Carcinoma With Residual Epstein-Barr Virus DNA After Radiation Therapy: A Biomarker-Driven, Phase 2 Trial.
    Liu X; Guo L; Xie FY; Hu WH; Chen MY; He QM; Xu ZM; Zhang CQ; Peng YL; Tang LL; Mao YP; Sun R; Li JB; Argiris A; Hui EP; Sun Y; Ma J
    Int J Radiat Oncol Biol Phys; 2022 Aug; 113(5):1063-1071. PubMed ID: 35550406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
    Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
    Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spontaneous remission of residual post-therapy plasma Epstein-Barr virus DNA and its prognostic implication in nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis.
    Zhang Y; Tang LL; Li YQ; Liu X; Liu Q; Ma J
    Int J Cancer; 2019 May; 144(9):2313-2319. PubMed ID: 30485420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
    Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
    Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of boost dose for T4 nasopharyngeal carcinoma with residual primary lesion after intensity-modulated radiotherapy.
    Fei Z; Xu T; Qiu X; Li M; Chen T; Li L; Huang C; Chen C
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2047-2055. PubMed ID: 33392660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy.
    Hui EP; Li WF; Ma BB; Lam WKJ; Chan KCA; Mo F; Ai QYH; King AD; Wong CH; Guo R; Poon DMC; Tong M; Li L; Lau TKH; Wong KCW; Lam DCM; Lo YMD; Ma J; Chan ATC
    Ann Oncol; 2020 Jun; 31(6):769-779. PubMed ID: 32217076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
    Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
    Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-radiation Plasma Epstein-Barr Virus DNA and Local Clinical Remission After Radical Intensity-modulated Radiation Therapy for Nasopharyngeal Carcinoma.
    Lee VH; Kwong DL; Leung TW; Choi CW; Lam KO; Sze CK; Ho P; Chan WL; Wong LS; Leung D
    Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):42-9. PubMed ID: 26482452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and prognostic value of pre-retreatment plasma epstein-barr virus DNA in locoregional recurrent nasopharyngeal carcinoma.
    Liu MZ; Fang SG; Huang W; Wang HY; Tian YM; Huang RD; Sun Z; Zhao C; Lu TX; Huang Y; Han F
    Cancer Med; 2019 Aug; 8(10):4633-4643. PubMed ID: 31268626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
    Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
    Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral chemotherapy versus observation alone in nasopharyngeal carcinoma patients with persistently detected circulating cell-free Epstein-Barr virus DNA during follow-up.
    Huang CL; Wang GY; Lou JH; Chen L; Li QJ; Li KP; Liang XY; Li YQ; Sun Y; Ma J; Guo R; Tang LL; Chen L
    Radiother Oncol; 2024 Jan; 190():110032. PubMed ID: 38007040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hopkins criteria for residual disease assessment after definitive radiotherapy in nasopharyngeal carcinoma.
    Liu Y; Long W; Wang G; Yang Y; Liu B; Fan W
    Cancer Med; 2020 Feb; 9(4):1328-1334. PubMed ID: 31875356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma.
    Leung SF; Chan KC; Ma BB; Hui EP; Mo F; Chow KC; Leung L; Chu KW; Zee B; Lo YM; Chan AT
    Ann Oncol; 2014 Jun; 25(6):1204-8. PubMed ID: 24638904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma: A Brief Review.
    Xue F; He X
    Methods Mol Biol; 2020; 2204():99-107. PubMed ID: 32710318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term monitoring of dynamic changes in plasma EBV DNA for improved prognosis prediction of nasopharyngeal carcinoma.
    Li W; Chen J; Liang B; Li Z; Li J; Yuan X; Wu S; Zeng F; Peng X; Li Y; Lu J; Zhao F; Liu X
    Cancer Med; 2021 Feb; 10(3):883-894. PubMed ID: 33378109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.
    Xu JY; Wei XL; Ren C; Zhang Y; Hu YF; Li JY; Chen JL; Wang YQ; Han F; Wang FH
    JAMA Netw Open; 2022 Mar; 5(3):e220587. PubMed ID: 35230439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in plasma EBV-DNA and immune status in patients with nasopharyngeal carcinoma after treatment with intensity-modulated radiotherapy.
    Chen Q; Hu W; Xiong H; Ying S; Ruan Y; Wu B; Lu H
    Diagn Pathol; 2019 Mar; 14(1):23. PubMed ID: 30871579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
    Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
    Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
    Zhang WR; Du YY; Guo CY; Zhou HX; Lin JY; Meng XH; Mo HY; Luo DH
    Cancer Res Treat; 2021 Oct; 53(4):991-1003. PubMed ID: 33494127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification.
    Lee VH; Kwong DL; Leung TW; Choi CW; O'Sullivan B; Lam KO; Lai V; Khong PL; Chan SK; Ng CY; Tong CC; Ho PP; Chan WL; Wong LS; Leung DK; Chan SY; So TH; Luk MY; Lee AW
    Int J Cancer; 2019 Apr; 144(7):1713-1722. PubMed ID: 30192385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.